As more American cities and states loosen their laws on psilocybin, clinicians have voiced a specific worry. People with depression, the concern goes, might turn to magic mushrooms on their own and walk away from therapists, prescriptions and supervised care. A study from the University of California San Diego School of Medicine suggests that is not what is happening.
Using nationally representative survey data, the researchers found that people with depression who use psilocybin seek mental health treatment at about the same rate as those who do not. What sets them apart is how often they say the care they receive falls short. The findings were published online in Psychological Medicine.
The central message, said Avery Eun, a second-year medical student at UC San Diego and the study’s first author, is that psilocybin users with depression “aren’t abandoning conventional mental health care.” She called that encouraging, while noting that these same people still feel their needs are going unmet, a gap she sees as an opening to understand what is missing.
A Question the Data Could Not Answer Before
Until now there had been no nationally representative evidence on whether people with depression were substituting psilocybin for supervised treatment. The obstacle was partly a matter of survey design. The National Survey on Drug Use and Health, the federal government’s main source of data on substance use, had asked only whether respondents had ever used psilocybin. The 2024 edition was the first to ask how recently.
That change matters, Eun said, because knowing someone used psilocybin within the past year, as opposed to at some point in their life, makes it possible to relate that use to their current mental health care.
The team analyzed responses from 6,793 people aged 12 and older who had experienced a major depressive episode in the previous year. An estimated 7.3 percent of them reported using psilocybin during that same year. Users were more likely to be younger, male, never married and employed full-time.
Same Care, More Unmet Need
On every measure of treatment the researchers examined, psilocybin use was not associated with getting less of it. Users were no less likely to receive outpatient, inpatient or telehealth mental health treatment, and no less likely to take prescription medication for depression.
The difference appeared in a question about perceived unmet need. Among psilocybin users, 52.0 percent said they had needed mental health treatment they did not get, compared with 33.9 percent of nonusers.
One reading of that gap is that people who feel conventional care is not doing enough are more inclined to try managing symptoms themselves, with psychedelics among the options. The researchers present this as a hypothesis that needs further study, not a conclusion. A single year of survey data cannot show which came first, the dissatisfaction or the drug use.
Not the Same as a Clinical Trial
The authors are careful to separate what people do on their own from what has been tested. Randomized controlled trials have found psilocybin-assisted therapy effective for depression, but in tightly monitored settings with structured dosing and psychological support. Naturalistic use has none of those safeguards. People often obtain the drug from inconsistent sources and take it without clinical oversight, so the safety and effectiveness seen in trials may not carry over.
They also suggest that policy could affect safety. Decriminalization, they note, may reduce stigma and make it easier for patients to tell their providers what they are taking.
For clinicians, Eun’s advice is not to assume that a patient who uses psilocybin is pulling away from care. The disclosure can instead start a conversation about why. If the patient is using it for therapeutic reasons, a clinician can ask whether conventional treatment is meeting their needs and, if not, what would help.
Eun’s co-authors are Kevin H. Yang of UCLA and Joseph J. Palamar of New York University. The research was funded by the National Institute on Drug Abuse. Palamar has consulted for the Washington-Baltimore High Intensity Drug Trafficking Areas program; the authors report no other potential conflicts of interest.
Endnotes
- Eun, A., Yang, K. H., & Palamar, J. J. (2026). “Psilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression.” Psychological Medicine.
- University of California San Diego (October 6, 2026). “Contrary to fears, psilocybin users with depression continue to seek treatment.” EurekAlert! https://www.eurekalert.org/news-releases/1146707

